Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Cerebral Vascular Disease Research Laboratories, Department of Neurology and Neuroscience Program, University of Miami School of Medicine, Miami, Florida 33101, United States.
CNS Neurol Disord Drug Targets. 2020;19(10):750-779. doi: 10.2174/1871527319666200910153827.
Epilepsy is the second most common neurological disease with abnormal neural activity involving the activation of various intracellular signalling transduction mechanisms. The molecular and system biology mechanisms responsible for epileptogenesis are not well defined or understood. Neuroinflammation, neurodegeneration and Epigenetic modification elicit epileptogenesis. The excessive neuronal activities in the brain are associated with neurochemical changes underlying the deleterious consequences of excitotoxicity. The prolonged repetitive excessive neuronal activities extended to brain tissue injury by the activation of microglia regulating abnormal neuroglia remodelling and monocyte infiltration in response to brain lesions inducing axonal sprouting contributing to neurodegeneration. The alteration of various downstream transduction pathways resulted in intracellular stress responses associating endoplasmic reticulum, mitochondrial and lysosomal dysfunction, activation of nucleases, proteases mediated neuronal death. The recently novel pharmacological agents modulate various receptors like mTOR, COX-2, TRK, JAK-STAT, epigenetic modulators and neurosteroids are used for attenuation of epileptogenesis. Whereas the various molecular changes like the mutation of the cell surface, nuclear receptor and ion channels focusing on repetitive episodic seizures have been explored by preclinical and clinical studies. Despite effective pharmacotherapy for epilepsy, the inadequate understanding of precise mechanisms, drug resistance and therapeutic failure are the current fundamental problems in epilepsy. Therefore, the novel pharmacological approaches evaluated for efficacy on experimental models of epilepsy need to be identified and validated. In addition, we need to understand the downstream signalling pathways of new targets for the treatment of epilepsy. This review emphasizes on the current state of novel molecular targets as therapeutic approaches and future directions for the management of epileptogenesis. Novel pharmacological approaches and clinical exploration are essential to make new frontiers in curing epilepsy.
癫痫是第二大常见的神经疾病,涉及异常的神经活动,涉及各种细胞内信号转导机制的激活。导致癫痫发作的分子和系统生物学机制尚未很好地定义或理解。神经炎症、神经退行性变和表观遗传修饰引发癫痫发作。大脑中过度的神经元活动与兴奋性毒性的有害后果下的神经化学变化有关。持续的重复过度神经元活动通过激活小胶质细胞延伸到脑组织损伤,小胶质细胞调节异常神经胶质重塑和单核细胞浸润,以响应导致轴突发芽的脑损伤,从而导致神经退行性变。各种下游转导途径的改变导致与内质网、线粒体和溶酶体功能障碍相关的细胞内应激反应,激活核酶、蛋白酶介导的神经元死亡。最近的新型药理学制剂调节各种受体,如 mTOR、COX-2、TRK、JAK-STAT、表观遗传调节剂和神经甾体,用于减轻癫痫发作。虽然针对复发性阵发性癫痫的细胞表面、核受体和离子通道的各种分子变化已经通过临床前和临床研究进行了探索,但针对癫痫的精确机制、耐药性和治疗失败的理解仍不充分,仍然是当前癫痫的基本问题。因此,需要确定和验证针对癫痫实验模型的有效药理学方法。此外,我们需要了解新靶点的下游信号通路,以治疗癫痫。这篇综述强调了新型分子靶点作为治疗方法的现状以及癫痫发作治疗的未来方向。新型药理学方法和临床探索对于开拓治疗癫痫的新前沿至关重要。